292 related articles for article (PubMed ID: 17597608)
21. Potent arterial antithrombotic effect of direct factor-Xa inhibition with ZK-807834 administered to coronary artery disease patients.
Zafar MU; Farkouh ME; Osende J; Shimbo D; Palencia S; Crook J; Leadley R; Fuster V; Chesebro JH
Thromb Haemost; 2007 Mar; 97(3):487-92. PubMed ID: 17334518
[TBL] [Abstract][Full Text] [Related]
22. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
23. Nonpeptide factor Xa inhibitors II. Antithrombotic evaluation in a rabbit model of electrically induced carotid artery thrombosis.
Wong PC; Crain EJ; Knabb RM; Meade RP; Quan ML; Watson CA; Wexler RR; Wright MR; Slee AM
J Pharmacol Exp Ther; 2000 Oct; 295(1):212-8. PubMed ID: 10991981
[TBL] [Abstract][Full Text] [Related]
24. Inhibition of arterial thrombosis by a soluble tissue factor mutant and active site-blocked factors IXa and Xa in the guinea pig.
Himber J; Refino CJ; Burcklen L; Roux S; Kirchhofer D
Thromb Haemost; 2001 Mar; 85(3):475-81. PubMed ID: 11307818
[TBL] [Abstract][Full Text] [Related]
25. Lipopolysaccharide augments venous and arterial thrombosis in the mouse.
Wang X
Thromb Res; 2008; 123(2):355-60. PubMed ID: 18448153
[TBL] [Abstract][Full Text] [Related]
26. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time.
Szalony JA; Suleymanov OD; Salyers AK; Panzer-Knodle SG; Blom JD; LaChance RM; Case BL; Parlow JJ; South MS; Wood RS; Nicholson NS
Thromb Res; 2003; 112(3):167-74. PubMed ID: 14967414
[TBL] [Abstract][Full Text] [Related]
27. Antithrombotic and antiplatelet activities of Korean red ginseng extract.
Jin YR; Yu JY; Lee JJ; You SH; Chung JH; Noh JY; Im JH; Han XH; Kim TJ; Shin KS; Wee JJ; Yun YP
Basic Clin Pharmacol Toxicol; 2007 Mar; 100(3):170-5. PubMed ID: 17309520
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of factor XIa as a new approach to anticoagulation.
Schumacher WA; Luettgen JM; Quan ML; Seiffert DA
Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):388-92. PubMed ID: 20139363
[TBL] [Abstract][Full Text] [Related]
29. Dual effects of sulfated D-galactans from the red algae Botryocladia occidentalis preventing thrombosis and inducing platelet aggregation.
Farias WR; Nazareth RA; Mourão PA
Thromb Haemost; 2001 Dec; 86(6):1540-6. PubMed ID: 11776325
[TBL] [Abstract][Full Text] [Related]
30. Three vehicle formulations for melagatran, a direct thrombin inhibitor, evaluated in a vena cava thrombosis model in the rat.
Elg M; Börjesson I; Carlsson S
Biopharm Drug Dispos; 2003 Sep; 24(6):251-7. PubMed ID: 12973822
[TBL] [Abstract][Full Text] [Related]
31. Is exogenous tissue plasminogen activator necessary for antithrombotic efficacy of an inhibitor of thrombin activatable fibrinolysis inhibitor (TAFI) in rats?
Bird E; Tamura J; Bostwick JS; Steinbacher TE; Stewart A; Liu Y; Baumann J; Feyen J; Tamasi J; Schumacher WA
Thromb Res; 2007; 120(4):549-58. PubMed ID: 17229457
[TBL] [Abstract][Full Text] [Related]
32. Antithrombotic effect of captopril and enalapril in young rats.
Buczko W; Kubik A; Kucharewicz I; Chabielska E
Pol J Pharmacol; 2004; 56(1):97-104. PubMed ID: 15047983
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis.
Jackson CV; Bailey BD; Shetler TJ
J Pharmacol Exp Ther; 2000 Dec; 295(3):967-71. PubMed ID: 11082430
[TBL] [Abstract][Full Text] [Related]
34. Antithrombotic effect of L-arginine in hypertensive rats.
Cylwik D; Mogielnicki A; Kramkowski K; Stokowski J; Buczko W
J Physiol Pharmacol; 2004 Sep; 55(3):563-74. PubMed ID: 15381827
[TBL] [Abstract][Full Text] [Related]
35. Antithrombotic efficacy of RPR208566, a novel factor Xa inhibitor, in a rat model of carotid artery thrombosis.
Heran C; Morgan S; Kasiewski C; Bostwick J; Bentley R; Klein S; Chu V; Brown K; Colussi D; Czekaj M; Perrone M; Leadley R
Eur J Pharmacol; 2000 Feb; 389(2-3):201-7. PubMed ID: 10688985
[TBL] [Abstract][Full Text] [Related]
36. Dose-dependent thrombus resolution due to oral plaminogen activator inhibitor (PAI)-1 inhibition with tiplaxtinin in a rat stenosis model of venous thrombosis.
Baxi S; Crandall DL; Meier TR; Wrobleski S; Hawley A; Farris D; Elokdah H; Sigler R; Schaub RG; Wakefield T; Myers D
Thromb Haemost; 2008 Apr; 99(4):749-58. PubMed ID: 18392333
[TBL] [Abstract][Full Text] [Related]
37. [Effect of a novel fibrinolytic enzyme FA-I on thrombosis and thrombolysis].
Wang GX; Liang CJ; Yao JY; Yuan JL; Wang JF
Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):288-91. PubMed ID: 19462909
[TBL] [Abstract][Full Text] [Related]
38. An inhibitory anti-factor IX antibody effectively reduces thrombus formation in a rat model of venous thrombosis.
Feuerstein GZ; Toomey JR; Valocik R; Koster P; Patel A; Blackburn MN
Thromb Haemost; 1999 Nov; 82(5):1443-5. PubMed ID: 10595635
[TBL] [Abstract][Full Text] [Related]
39. Antithrombotic properties of SSR182289A, a new, orally active thrombin inhibitor.
Lorrain J; Millet L; Lechaire I; Lochot S; Ferrari P; Visconte C; Sainte-Marie M; Lunven C; Berry CN; Schaeffer P; Herbert JM; O'Connor SE
J Pharmacol Exp Ther; 2003 Feb; 304(2):567-74. PubMed ID: 12538808
[TBL] [Abstract][Full Text] [Related]
40. Active site-inactivated factor VIIa prevents thrombosis without increased surgical bleeding: topical and intravenous administration in a rat model of deep arterial injury.
Söderström T; Hedner U; Arnljots B
J Vasc Surg; 2001 May; 33(5):1072-9. PubMed ID: 11331851
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
